AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Placental Vascularization Using Contrast Ultrasound

RecruitingPhase 3Ages 18 Years - 64 YearsFemaleCentral Hospital, Nancy, France
💬

In plain words

What the trial is, and whether it could suit you

Preeclampsia and intrauterine growth restriction (IUGR) are two principal complications of pregnancy. These diseases are related to placental dysfunction nevertheless knowledge of its pathophysiological mechanisms remains inadequate. No etiological treatment for these pathologies is available. Inducing birth is the only way to prevent the occurrence of these complications (such as fetal death in utero. Therefore, a better understanding of placental vascularization under pathological and physiological conditions is necessary. This placental vascularization evolves throughout gestation. Histological studies have improved our knowledge of placental vascular pathologies; however, these are ex vivo data that only provide an incomplete reflection of placental function. In vivo placental studies are therefore essential to understand the mechanisms of placental perfusion. Currently, these stud

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adult woman (age ≥18 years), * Gestational age between 16 GW + 0 days and 38 GW + 6 days, * Singleton pregnancy, * Whose request of a medical termination of pregnancy (IMG) has been formulated and accepted in a written form by the Centre Pluridisciplinaire de Diagnostic Prénatal (CPDPN) of the Centre Hospitalier Régional Universaitaire (CHRU) de Nancy, * Affiliated to the social security system or benefit from such a system, * Having received full information and having signed an informed consent form. Criteria specific to patients in the "growth restriction" group: \- Severe growth restriction defined by an estimation of foetal weight below the 3rd percentile using ultrasound performed no more than 15 days prior to the IMG (the diagnosis must be established at the time of the request for IMG in routine care). Exclusion Criteria: * Person who do not speak French * Any medical condition contraindicating the administration of SonoVue, in particular: * Hypersensitivity to sulfur hexafluoride or to one of the other components of SonoVue® such as polyethylene glycol (PEG), * Women with recent acute coronary syndrome or unstable ischaemic heart disease, * Women with a right-to-left shunt, severe pulmonary arterial hypertension (pulmonary arterial pressure \> 90 mmHg), uncontrolled systemic hypertension and women suffering from respiratory distress syndrome. * Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code: * Breast-feeding mother * Minor (not emancipated) * An adult subject to a legal protection (guardianship, curatorship, safeguard of justice) * An adult unable to give consent * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1
💊

What it tests

  • SonoVue
📍

Where

1 site
CHRU de NANCY
Nancy, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy